The ability of tumors to develop resistance to cytotoxic therapies has been a
major obstacle in the clinical management of cancer. In addition, dose-limiting toxicity
represents yet another impediment in the application of traditional therapeutics. To
enhance the sensitivity of tumors to radio-therapeutics, researchers are increasingly
turning to nitric oxide for its potential as a powerful adjuvant to existing therapies.
Here, we review the aptitude of nitric oxide to serve as a radio-sensitizing, adjuvant
therapeutic for the clinical management of cancer.
Keywords: Adjuvant therapy, cancer, nitric oxide, oncology, radiotherapy,
therapeutic delivery.
